If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact us.

 


 

30.03.2021

AiCuris expands its Management with Prof. Dr. Hubert Tr├╝bel joining as Chief Medical Officer and the Appointment of Dr. Tamara Pfaff, Head of Preclinical Development, to the Management Team

Prof. Hubert Tr├╝bel joined AiCuris as Head of Clinical Development and Chief Medical Officer. In addition, the Head of Preclinical Development, Dr. Tamara Pfaff, was also appointed to the management team effective April 1, 2021

more ...

23.03.2021

AiCuris to participate BIO-Europe Spring panel ÔÇťPandemic therapeutics: treating COVID-19 and beyondÔÇŁ

more ...

18.03.2021

Meet us at BIO-Europe® Spring Digital 2021

AiCuris will be present throughout the BIO-Europe® Spring Digital 2021 partnering conference.

more ...

01.02.2021

AiCuris changes its legal form: AiCuris Anti-infective Cures GmbH becomes AiCuris AG

Transition will support the Company in exploring additional opportunities for future growth

more ...

13.01.2021

AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative

AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative

more ...

08.01.2021

AiCuris to Present at the 39th Annual J.P. Morgan Healthcare Conference

AiCuris to Present at the 39th Annual J.P. Morgan Healthcare Conference

more ...